This weekend I attended a regional lung cancer patient summit sponsored by the Lungevity Foundation in Columbus, Ohio. I got to meet other people with lung cancer, as well as care- givers, researchers, and advocates. Many of the lung cancer patients had metastatic disease (like me) and were multi-year survivors, so it was reassuring to meet other folks on targeted therapies and immunotherapies who are doing well.
We got to hear an inspiring keynote talk from Dr. David Carbone, who is director of The James Cancer Hospital Thoracic Oncology Center at The Ohio State University, and who used to work in here in Nashville at Vanderbilt. Dr. Carbone had good news for us, but first, he gave us a little historical background, most of which I already knew. Back in the bad old days, in the 1990s, when he first began treating lung cancer patients, there wasn't much to offer by way of treatment to those with metastatic disease. Patients with late-stage lung cancer usually died within a few months of diagnosis. But, things have really changed for the better, and with new treatments, many of us with metastatic disease are living years (not necessarily lots and lots of years, but at least we're using a plural form) instead of months. Folks in attendance were living proof of that! Dr. Carbone also said that he'd seen patients with advanced disease have complete responses to treatment, especially immunotherapy, and they are seeing durable responses beyond the five-year survival mark, even after the treatment has stopped. So....Dr. Carbone said that it might even be possible to talk about some of these patients as being cured of metastatic disease. Uh huh. He used the "C" word. Not for a lot of patients. Just a few. But cured. Of what had previously been an incurable metastatic disease. So that was good to hear.
As a rule, oncologists are trained to say to patients with metastatic lung cancer "you have an incurable cancer, but it is treatable." They no longer use the word "terminal." We are told that "each person's cancer is different", and the hope is our disease can be managed as a chronic illness, that we'll move from treatment to treatment for as long as we can, until we run out of options. And for the most part, that is still true. And for the most part, we still risk running out of options, especially those of us who are on "breakthrough" and "cutting edge" therapies. That's the thing about cutting edge; it means you're on the edge.
The genetics of lung cancer are more complicated than they are for some other cancers; there are different types of lung cancer, and over 300 possible genetic drivers for most lung cancers. Plus with targeted therapies, new mutations develop resistance to treatment, so it's kind of like a crazy game of wack-a-mole trying to keep the disease pinned down.
But Dr. Carbone's optimism was contagious. I hope a cure for lung cancer will be too.
Sunday, October 28, 2018
Monday, October 22, 2018
I Have These Conversations
Every once in awhile I find myself in a conversation about cancer with someone who, upon learning my diagnosis, holds forth on the elaborate big pharma conspiracy to hide the cure for cancer so that we'll all have to keep paying for expensive treatments that only make us sicker. I'm told, for instance, that studies on intravenous use of Vitamin C to cure cancer have been suppressed (they haven't been; I've read them) because they prove that this simple technique cures cancer (it doesn't) and would put big pharma out of business (it won't). Oh, and it's not just big pharma, I'm told, that is part of the conspiracy to keep the cure away from patsies like us desperate cancer patients who show up for clinical trials, scans, chemo, radiation, targeted treatments, immuno-therapies, and surgeries. In fact, as my would-be enlightener will point out, the entire medical establishment aims at keeping us all sick unto death for the sake of profit.
And I get it. Greed is ever-present, and no industry chugging along in a capitalist culture is immune from tendencies toward profiteering. (Which is why, by the way, we might want to give more scrutiny to the fact that we encourage for-profit models in areas like health care, elder care, day care, education, and other efforts on behalf of the greater good, but that is another argument for another day.) Yes, there have been plenty of scandals involving the pharmaceutical industry, and yes, many hospitals, clinics, and ERs are full of repeat customers because treatments have poor outcomes due to myriad failures in the way we, as a culture, practice medicine and view wellness. Bureaucracy, over-regulation, under-regulation, terrible communication, and outright incompetence seem to prevail and offer us good reasons to distrust the health care industry. The inequities built into our health care system alone make it a scandal, and ethical questions about clinical trials and treatment development abound.
But working both inside and outside that entirely dysfuntional machine are some pretty dedicated cancer researchers who, if they could find a panacea for all cancer, would gladly wash out their petri dishes and turn their time and talents to other useful things. So here's what I have to say to the tipsy party guest who regaled me with his cancer-cure conspiracy theories a few nights ago. Read the actual medical literature. Go to a few cancer conferences like those sponsored by ASCO or to patient summits like those offered by The Lungevity Foundation. Talk to some researchers. Talk to more patients like me who participate in clinical trials. See what research projects non-profit foundations are funding. Visit a patient advocacy site like The ROS1ders. Cruise the listings on ClinicalTrials.gov hoping for a miracle cure. Learn that "cancer" isn't one thing, that its cure will never be found in one silver bullet or in prevention-only strategies, but rather in each data point collected, each pattern detected, each genetic code cracked. Cancer research is a molecular, genetics, big data long game now. And if you, dear reader, know someone spouting ill-informed notions about the Great Cancer Cure Conspiracy, suggest that what that person is doing, rather than enlightening anyone, is diminishing the existing and ongoing research that really is curing cancer, one clinical trial and one patient at a time.
And I get it. Greed is ever-present, and no industry chugging along in a capitalist culture is immune from tendencies toward profiteering. (Which is why, by the way, we might want to give more scrutiny to the fact that we encourage for-profit models in areas like health care, elder care, day care, education, and other efforts on behalf of the greater good, but that is another argument for another day.) Yes, there have been plenty of scandals involving the pharmaceutical industry, and yes, many hospitals, clinics, and ERs are full of repeat customers because treatments have poor outcomes due to myriad failures in the way we, as a culture, practice medicine and view wellness. Bureaucracy, over-regulation, under-regulation, terrible communication, and outright incompetence seem to prevail and offer us good reasons to distrust the health care industry. The inequities built into our health care system alone make it a scandal, and ethical questions about clinical trials and treatment development abound.
But working both inside and outside that entirely dysfuntional machine are some pretty dedicated cancer researchers who, if they could find a panacea for all cancer, would gladly wash out their petri dishes and turn their time and talents to other useful things. So here's what I have to say to the tipsy party guest who regaled me with his cancer-cure conspiracy theories a few nights ago. Read the actual medical literature. Go to a few cancer conferences like those sponsored by ASCO or to patient summits like those offered by The Lungevity Foundation. Talk to some researchers. Talk to more patients like me who participate in clinical trials. See what research projects non-profit foundations are funding. Visit a patient advocacy site like The ROS1ders. Cruise the listings on ClinicalTrials.gov hoping for a miracle cure. Learn that "cancer" isn't one thing, that its cure will never be found in one silver bullet or in prevention-only strategies, but rather in each data point collected, each pattern detected, each genetic code cracked. Cancer research is a molecular, genetics, big data long game now. And if you, dear reader, know someone spouting ill-informed notions about the Great Cancer Cure Conspiracy, suggest that what that person is doing, rather than enlightening anyone, is diminishing the existing and ongoing research that really is curing cancer, one clinical trial and one patient at a time.
Wednesday, October 10, 2018
Eighteen or One Hundred?
I know a hundred people, at least. Well actually I know a lot more than a hundred people, but for the sake of argument I'm going to stick with that number. And by "know", I don't mean "know well". I mean these are just a hundred people who are sort of in my regular orbit, some of whom I know well, others, not so well. I'm guessing, too, that maybe most of us know at least a hundred people – friends, family members, people from work or school or yoga class, the regulars at the coffee shop, a favorite barista, a hairstylist or barber, the waitress at the breakfast joint who calls you baby. Okay, let's count some of the social media friends; we just like each other's posts, and somehow, these people in cyberspace have become part of that crowd of one hundred.
So think about those hundred people. And now, imagine (God forbid!) that they have all been diagnosed with lung cancer. And fast forward five years. Only eighteen of them (statistically speaking) will be alive.
That's right. According to the most recent statistics, only 18% of people diagnosed with lung cancer live longer than five years. And that's an improvement over a number which hasn't changed much in a few decades.
I was pretty shocked when I read that number. And the statistics are even worse for someone like me, diagnosed in a late metastatic stage, which also happens to be the most common stage for diagnosis. Why is the survival rate so low? There are a number of reasons. We don't routinely screen for lung cancer in the way we do for other cancers to detect and treat it early; we don't fund lung cancer research at the levels that we fund research into other types of cancer; lung cancer symptoms rarely present in an early stage, so by the time they are diagnosed, many lung cancer patients already have incurable metastatic disease. Likely the overarching reason for all of these issues is that lung cancer is still a highly stigmatized disease due to the mistaken belief that only those with the poor health practice of cigarette smoking will get it.
Last year at this time I did not have the ability to recite lung cancer statistics off the top of my head, nor did I ever think that I'd be included in those statistics. I know too many lung cancer numbers, and make myself obnoxious at dinner parties reciting them. But, I refuse to accept the grim prognosis those numbers tell. The pace of research is picking up, sustained by a number of organizations like The Bonnie J. Addario Lung Cancer Foundation and Lungevity, which are focused on ending lung cancer. I think our chances are improving all the time. In fact, I'd like to think that when I celebrate my five-year Cancerversary, I'll know at least a hundred other people with lung cancer who are celebrating theirs.
So think about those hundred people. And now, imagine (God forbid!) that they have all been diagnosed with lung cancer. And fast forward five years. Only eighteen of them (statistically speaking) will be alive.
That's right. According to the most recent statistics, only 18% of people diagnosed with lung cancer live longer than five years. And that's an improvement over a number which hasn't changed much in a few decades.
I was pretty shocked when I read that number. And the statistics are even worse for someone like me, diagnosed in a late metastatic stage, which also happens to be the most common stage for diagnosis. Why is the survival rate so low? There are a number of reasons. We don't routinely screen for lung cancer in the way we do for other cancers to detect and treat it early; we don't fund lung cancer research at the levels that we fund research into other types of cancer; lung cancer symptoms rarely present in an early stage, so by the time they are diagnosed, many lung cancer patients already have incurable metastatic disease. Likely the overarching reason for all of these issues is that lung cancer is still a highly stigmatized disease due to the mistaken belief that only those with the poor health practice of cigarette smoking will get it.
Last year at this time I did not have the ability to recite lung cancer statistics off the top of my head, nor did I ever think that I'd be included in those statistics. I know too many lung cancer numbers, and make myself obnoxious at dinner parties reciting them. But, I refuse to accept the grim prognosis those numbers tell. The pace of research is picking up, sustained by a number of organizations like The Bonnie J. Addario Lung Cancer Foundation and Lungevity, which are focused on ending lung cancer. I think our chances are improving all the time. In fact, I'd like to think that when I celebrate my five-year Cancerversary, I'll know at least a hundred other people with lung cancer who are celebrating theirs.
Thursday, September 13, 2018
Hello, I'm NED!
![]() |
| Today's foot attire. |
Even though it's a horrible thing to have cancer, and even though I had an awful setback in treatment in May, and even though I'll likely be having to treat this disease for the rest of my life, so many other things have gone right that I feel incredibly fortunate most of the time. Through a happy chain of events, I found myself in touch with the right people who had the right information at the right time to help me get access to this trial. I had the indispensable help of the ROS1ders, especially Patty, who was the first person with lung cancer to tell me I could survive it, and who is always just a phone call away. And in the couple of days back in May when I was having to make hard decisions about treatment, two of my best friends, Claudia and Rebel, swooped in to cheer me on. They urged me to pursue the trial and helped me gather and send off all the clinical records I needed to be considered for it, which involved some serious running around to multiple clinics in midtown Nashville on a hot day. It's great having your own personal cheering squad when you're terrified. Once I got to Boston, my sister Michele and two of my nieces met me and my husband John there, schlepping over on a long drive from New York after just having a long trip home from visiting me in Nashville! Another cheering squad to the rescue as John and I waited to learn if I could get in the trial. I did qualify, and that has meant monthly trips from Nashville to Boston, so again, I have been fortunate to have the resources and to have been given some generous gifts to fund my travel to Boston to follow the protocol. Not all cancer patients who could benefit from trials can get access because the sites are often far away and the cost of travel prohibitive.
So, science yes, but grace too.
And unconditional love and support from my husband John and stepdaughter Rachel for my decisions. Their good spirits, patience, generosity, and love have sustained me. Being a caregiver to someone with cancer is never easy, especially when that someone is ornery me.
What does all this mean for my prognosis? Well, I still actually have cancer. But now, we're treating it more like a chronic illness instead of a soon-to-be fatal one. Those of us in the lung cancer community know, though, that things can turn ugly quite suddenly, and no matter what the treatment plan is, we're always thinking about what could happen with the next set of scans. I'll keep taking lorlatinib for as long as it keeps the cancer pinned to the mat. If the disease gets a second wind and rises up, well, it just so happens I have a hook-up with a rock star cancer researcher in Boston who studies the disease's mechanisms of resistance to treatment, and she will, by then, have discovered more about what to do next. Those discoveries will benefit not just me, but so many others who have lung and other cancers that need to be treated at the molecular level. That, my friends, is why we have to keep pushing to make more funding available for lung cancer research. And one of these days, I'll quit pestering you for donations, because all those dollars you'll have contributed will have added up to a cure!
Wednesday, August 29, 2018
The Money Thermometer
I wanted to write some sort of witty post that would make readers laugh and set everyone at ease so I could ask you all for money. (I promise it's not for me. Well actually it is, sort of, but I'll get to that.) Anyway, as I tried to write that witty, magic, purse-and-wallet-opening post, every pathology I've ever developed from my semi-abusive, co-dependent relationship with capitalism and the free-market economy came crashing down on my psyche, and all I could think about was the money thermometer. You know, those thermometer illustrations non-profit organizations use to show how their fund drives are going? Well, I started imagining what one would look like showing off my fundraising efforts for lung cancer research, and it was kind of embarrassing.
Oh, you didn't know I was raising money for lung cancer research? Hmmm, that might explain why my imaginary money thermometer is recording sub-zero temperatures.
So I guess I'd better get on it, right? I know, I know...so many worthy causes out there! How does one choose? For me, this year, the choice was easy and obvious. In fact, it wasn't even a choice; it was a directive.
I am a direct beneficiary of on-going lung cancer research. In May of 2018, I learned my first-line, standard-of-care treatment failed, and the lung cancer that had been kept in check by crizotinib had mutated, gotten loose, and had metastasized to my brain. Thankfully, I was fortunate enough to enter a clinical trial for a breakthrough targeted therapy that has gotten the metastatic disease under control. In May, I didn't know if I would live through the summer. This week, I gratefully went back to my teaching job. While the doctors don't know exactly how long this new treatment will keep the cancer in check (average progression-free-survival on lorlatinib is around 20 months), and we don't know yet what my next line of treatment will be, I remain optimistic that, with the help of continued research funding, the science will outpace the disease. (Fingers and toes crossed and prayers for clean September scans please!) I'm lucky. There is actually more than one line of treatment for my type of lung cancer. Many other lung cancer patients have even more limited options than I do!*
As I've noted here before, lung cancer is one of the most deadly cancers, one of the most stigmatized, and, as a result, one of the least funded in terms of research. Science has made some amazing advances in treatment in the last decade with new immunotherapies and targeted therapies, but more people are still dying from lung cancer than they are from breast, colorectal, and prostate cancers combined. Did you know that breast cancer has a 90% five-year survival rate? That's due to substantial early detection practices and decades of generous and reliable research funding. The five-year survival rate for lung cancer is 18% if detected early. See more interesting statistics here: Lung Cancer Facts.
So if you didn't know it before, you know it now. I'm raising money for lung cancer research. As long as I live or until there is a cure, I will be raising money for lung cancer research. I'll try not to be too obnoxious about it. But I'm going to ask. And ask. And ask. And if you don't feel you can help this time, that's totally okay. I'll ask again. And again. There will be ample opportunity. And when the spirit moves you at last, you can help by donating to one of the projects listed here: Giving to Research. I don't have any material incentive to offer, other than the tax breaks my particular pet projects bring you. There's no swag. No one will say your name on the radio or TV. But you'll know what you did. And what you did, it's real good, my friend, real good! You don't need a money thermometer to tell you that.
Oh, you didn't know I was raising money for lung cancer research? Hmmm, that might explain why my imaginary money thermometer is recording sub-zero temperatures.
So I guess I'd better get on it, right? I know, I know...so many worthy causes out there! How does one choose? For me, this year, the choice was easy and obvious. In fact, it wasn't even a choice; it was a directive.
I am a direct beneficiary of on-going lung cancer research. In May of 2018, I learned my first-line, standard-of-care treatment failed, and the lung cancer that had been kept in check by crizotinib had mutated, gotten loose, and had metastasized to my brain. Thankfully, I was fortunate enough to enter a clinical trial for a breakthrough targeted therapy that has gotten the metastatic disease under control. In May, I didn't know if I would live through the summer. This week, I gratefully went back to my teaching job. While the doctors don't know exactly how long this new treatment will keep the cancer in check (average progression-free-survival on lorlatinib is around 20 months), and we don't know yet what my next line of treatment will be, I remain optimistic that, with the help of continued research funding, the science will outpace the disease. (Fingers and toes crossed and prayers for clean September scans please!) I'm lucky. There is actually more than one line of treatment for my type of lung cancer. Many other lung cancer patients have even more limited options than I do!*
As I've noted here before, lung cancer is one of the most deadly cancers, one of the most stigmatized, and, as a result, one of the least funded in terms of research. Science has made some amazing advances in treatment in the last decade with new immunotherapies and targeted therapies, but more people are still dying from lung cancer than they are from breast, colorectal, and prostate cancers combined. Did you know that breast cancer has a 90% five-year survival rate? That's due to substantial early detection practices and decades of generous and reliable research funding. The five-year survival rate for lung cancer is 18% if detected early. See more interesting statistics here: Lung Cancer Facts.
So if you didn't know it before, you know it now. I'm raising money for lung cancer research. As long as I live or until there is a cure, I will be raising money for lung cancer research. I'll try not to be too obnoxious about it. But I'm going to ask. And ask. And ask. And if you don't feel you can help this time, that's totally okay. I'll ask again. And again. There will be ample opportunity. And when the spirit moves you at last, you can help by donating to one of the projects listed here: Giving to Research. I don't have any material incentive to offer, other than the tax breaks my particular pet projects bring you. There's no swag. No one will say your name on the radio or TV. But you'll know what you did. And what you did, it's real good, my friend, real good! You don't need a money thermometer to tell you that.
*In memory of my classmate, Renee Nasby Baker, who lost her life to lung cancer.
Sunday, August 19, 2018
Resilience and a Good Report
This week I began my fourth cycle of lorlatinib, the targeted therapy that has chased off cancer metastases in my brain and resolved all the tumors in my lungs. As I get myself around Boston on the T like a pro now, it hardly seems like three months have passed since I showed up at Yawkey Cancer Center Suite 7B to enter Dr. Alice Shaw's clinical trial. But as I made my way from the Red Line stop across the now-familiar intersection and into Mass General for my clinic visit, I realized how oddly normal, even routine it has become to be doing that very thing. Despite this routine familiarity, I remain mindful of the fact that what I am getting to do here in Boston is remarkable. This research study in which I am fortunate enough to participate is moving cancer treatment forward in important ways and is fueling a paradigm shift that will, I am certain, lead to better treatments, and eventually more cures for more kinds of cancers, and very soon.
This last visit made me aware, too, of how resilient the body can be. When I began taking this drug, my liver enzyme count sky-rocketed, so much so that I had to get blood drawn every two weeks to monitor the response to the new drug. I am happy to report that my liver has recovered from its initial lorlatinib shock and is performing nicely again. And so, wine and bourbon (in small amounts) are back on the menu, yay! The brain fog has lifted as well; I still have some memory issues and word finding issues, and multitasking is super hard, but my thinking doesn't feel as...gooey. The annoying neuropathy in my hands continues, though it is not as severe. Less happily, flying to Boston exacerbated the edema in my legs, so now I have an unfortunate case of cankles.
The nicest part of this last trip (I mean besides getting my hands on more of that life-saving medicine) was the company! I got to spend a few days with my brilliant and beautiful pal Rebel, who lives up to her name in more delightful
ways than I can even say. She is an expert on many things (the career of actress Betty Buckley, for example) and is especially gifted at pointing out which movie stars people on the train resemble. Rebel is also the best director of cell phone selfies I know. Plus she keeps my emotional shit together, insists I floss, and makes sure I stay hydrated. I'm grateful to travel under her supervision.
This coming week I'll return to work, preparing to teach a full load of classes and doing some advising, then beginning classes on the 27th. Back in May, when I learned Xalkori had failed and I had mets in my brain, I just stopped thinking about school. I'd already decided to forgo summer teaching, for the first time in my entire career, in order to spend my summer visiting family and friends, so with the new diagnosis, that time became paramount. And when I started lorlatinib and felt like my brain was churning through cold molasses, I started seriously looking at retirement; I was pretty certain I couldn't go back to school if I couldn't remember a conversation from five minutes ago or find the words I was looking for to express a simple idea. And though I'm not feeling like my brain function is 100 percent, it's a good bit better, and I have been persuaded to make a new attempt at "normalcy" and return to work. So, that's the plan. I only need to get my neuropathic hands working a little better in the morning, or just give up buttoned shirts in favor of pullovers.
I've got scans coming up in early September, so I'm hoping the lorlatinib is still holding the cancer in check and that the plan will still roll. It's been an amazing summer, full of blessings. I stand full of gratitude and optimism on the cusp of a new season to come.
This last visit made me aware, too, of how resilient the body can be. When I began taking this drug, my liver enzyme count sky-rocketed, so much so that I had to get blood drawn every two weeks to monitor the response to the new drug. I am happy to report that my liver has recovered from its initial lorlatinib shock and is performing nicely again. And so, wine and bourbon (in small amounts) are back on the menu, yay! The brain fog has lifted as well; I still have some memory issues and word finding issues, and multitasking is super hard, but my thinking doesn't feel as...gooey. The annoying neuropathy in my hands continues, though it is not as severe. Less happily, flying to Boston exacerbated the edema in my legs, so now I have an unfortunate case of cankles.
The nicest part of this last trip (I mean besides getting my hands on more of that life-saving medicine) was the company! I got to spend a few days with my brilliant and beautiful pal Rebel, who lives up to her name in more delightful
![]() |
| Rebel being fabulous in the elevator. |
This coming week I'll return to work, preparing to teach a full load of classes and doing some advising, then beginning classes on the 27th. Back in May, when I learned Xalkori had failed and I had mets in my brain, I just stopped thinking about school. I'd already decided to forgo summer teaching, for the first time in my entire career, in order to spend my summer visiting family and friends, so with the new diagnosis, that time became paramount. And when I started lorlatinib and felt like my brain was churning through cold molasses, I started seriously looking at retirement; I was pretty certain I couldn't go back to school if I couldn't remember a conversation from five minutes ago or find the words I was looking for to express a simple idea. And though I'm not feeling like my brain function is 100 percent, it's a good bit better, and I have been persuaded to make a new attempt at "normalcy" and return to work. So, that's the plan. I only need to get my neuropathic hands working a little better in the morning, or just give up buttoned shirts in favor of pullovers.
I've got scans coming up in early September, so I'm hoping the lorlatinib is still holding the cancer in check and that the plan will still roll. It's been an amazing summer, full of blessings. I stand full of gratitude and optimism on the cusp of a new season to come.
Wednesday, August 8, 2018
Durability
In July I received the spectacular news that I have had a "nearly complete response" to lorlatinib, a new cancer medication (so new it's still in clinical trials) that I began taking in late May. Not only was the response nearly complete; it was fast! All tumors in my lungs and lymph nodes are gone, and all fuckles but one tiny speck in my brain have disappeared as well. So, everyone, family, friends, medical team, especially me, was/is happy and grateful. Because I have stage iv disease, which means the cancer is still hanging out in my body and can become resistant to lorlatinib at any time, we can't call me "cured," and we will have to continue "surveillance" (MRI and CT scans every three months) so that if cancer shows up again (which it likely will, stage iv disease and all), we can pounce on it with another treatment. This is what we mean by stage iv cancer becoming a "managed" disease rather than a fatal one.
Another word we get to use a lot now is "durable," as in "We hope this will be a 'durable' response to treatment." Until I got sick with cancer, I never used the word "durable" in relation to health. Certain kinds of upholstery fabric maybe, or Amish barns are durable, but a response to medical treatment...well, either you are cured or you aren't, right? Definitely not in Cancerland (and other lands too) – welcome to another one of cancer's vocabulary lessons. A "durable" response to treatment in Cancerland is one year or more of DFS or PFS (disease-free or progression-free survival). Oh, and a side note here. Isn't it weird that cancer "progresses", that we have "disease progression"? I'd hardly call the spread of cancer progress.
![]() |
| Opus 40 Environmental Sculpture, Saugerties NY |
Anyway, in mulling over this idea of "durable" response to treatment, I consider what is designed to endure, what we want to last. 1) Big things we build – monuments, roads, houses, barns, libraries. 2) Things we buy – cars, shoes, backpacks, refrigerators. 3) Things we make – sculptures, gardens, poems, promises. All designed to last.
They don't, of course. Well, some things last more than others. Art. Art lasts. For awhile. (As an artist, I'm required to say that.) But libraries are sacked and burned at the fall of empire; roads and buildings crumble; cars go to the junk heap, gardens get gated, and so on. And then there's climate change, nuclear proliferation, superviruses, and the demise of the Oxford comma to worry about. It would seem, then, as a race, our prospects need improving.
![]() |
| Old Pick-up Truck Used for Target Practice |
And yet. Mountains. Wide rivers.
![]() |
| Catskill Mountains, Delaware County NY |
![]() |
| Hudson River from The Walkway Over the Hudson |
![]() |
| Dingle Hill Daisies |
The great and certain circle of seasons.
And, perpetually, hope – that little boat we keep rowing.
We can't not. It's how we're made.
And that's what I call a durable response.
We can't not. It's how we're made.
And that's what I call a durable response.
![]() |
| Saugerties Lighthouse |
Subscribe to:
Posts (Atom)
Number Nine Number Nine Number Nine
Nine Crows I have the great privilege of saying that this month, almost a week ago on November 9, I marked my 9th year living with a late st...
-
It's the first day of spring, officially. It's also my birthday, the double nickel year -- 55. A few months ago I wasn't so sure...
-
Welcome to Sojourn & Stardust. In November of 2017, I was diagnosed with Stage IV adenocarcinoma, a non-small cell lung cancer. Presen...
-
Disease progression. That's what my scans from this week show...tumor growth in the lungs and metastases to the brain. Apparently my w...











